| Document and Entity Information | 9 Months Ended | |
| Sep. 30, 2013 | Oct. 17, 2013 | |
| Document Information [Line Items] | ' | ' |
| Document Type | '10-Q | ' |
| Amendment Flag | 'false | ' |
| Document Period End Date | 30-Sep-13 | ' |
| Document Fiscal Year Focus | '2013 | ' |
| Document Fiscal Period Focus | 'Q3 | ' |
| Trading Symbol | 'CIK0001578845 | ' |
| Entity Registrant Name | 'ACTAVIS PLC | ' |
| Entity Central Index Key | '0001578845 | ' |
| Current Fiscal Year End Date | '--12-31 | ' |
| Entity Filer Category | 'Non-accelerated Filer | ' |
| Entity Common Stock, Shares Outstanding | ' | 174,047,953 |
| Deferred Ordinary Shares [Member] | ' | ' |
| Document Information [Line Items] | ' | ' |
| Entity Common Stock, Shares Outstanding | ' | 40,000 |
| Condensed Consolidated Balance Sheet (USD $) | Sep. 30, 2013 |
| Current Assets: | ' |
| Cash and cash equivalents | $54,101 |
| Total current assets | 54,101 |
| Total assets | 54,101 |
| LIABILITIES AND EQUITY | ' |
| Total liabilities | ' |
| Commitments and contingencies | ' |
| Equity: | ' |
| Ordinary and deferred ordinary shares | 53,121 |
| Additional paid-in capital | 10 |
| Retained earnings | 970 |
| Total equity | 54,101 |
| Total liabilities and equity | $54,101 |
| Condensed Consolidated Statement of Operations (USD $) | 3 Months Ended | 4 Months Ended |
| Sep. 30, 2013 | Sep. 30, 2013 | |
| Net revenues | ' | ' |
| Operating (income) expense: | ' | ' |
| General and administrative | -970 | -970 |
| Total operating (income) expense | -970 | -970 |
| Operating income | 970 | 970 |
| Net income | $970 | $970 |
| Earnings per share: | ' | ' |
| Ordinary shares - Basic & Diluted | $138.51 | $138.51 |
| Weighted average ordinary shares outstanding: | ' | ' |
| Ordinary shares - Basic & Diluted | 7 | 7 |
| Deferred Shares [Member] | ' | ' |
| Earnings per share: | ' | ' |
| Ordinary shares - Basic & Diluted | $0.07 | $0.13 |
| Weighted average ordinary shares outstanding: | ' | ' |
| Ordinary shares - Basic & Diluted | 13,478 | 7,381 |
| Condensed Consolidated Statement of Comprehensive Income (USD $) | 3 Months Ended | 4 Months Ended |
| Sep. 30, 2013 | Sep. 30, 2013 | |
| Statement Of Income And Comprehensive Income [Abstract] | ' | ' |
| Net income | $970 | $970 |
| Other comprehensive income | ' | ' |
| Comprehensive income | $970 | $970 |
| Condensed Consolidated Statement of Cash Flows (USD $) | 4 Months Ended |
| Sep. 30, 2013 | |
| Cash Flows From Operating Activities: | ' |
| Net income | $970 |
| Net cash provided by operating activities | 970 |
| Cash Flows From Financing Activities: | ' |
| Proceeds from issuance of equity to Matsack | 53,131 |
| Net cash provided by financing activities | 53,131 |
| Net increase in cash and cash equivalents | 54,101 |
| Cash at end of period | $54,101 |
| General | 9 Months Ended | |||
| Sep. 30, 2013 | ||||
| Accounting Policies [Abstract] | ' | |||
| General | ' | |||
| NOTE 1 – General | ||||
| Actavis plc (formerly known as Actavis Limited) was incorporated in Ireland on May 16, 2013 as a private limited company and re-registered effective September 18, 2013 as a public limited company. It was established for the purpose of facilitating the business combination between Actavis, Inc. and Warner Chilcott plc (“Warner Chilcott”). As of September 30, 2013, the principal activity of Actavis plc (“Actavis plc”, “Company” or “we”) was investment holding. On October 1, 2013, the Company became the successor registrant to Actavis, Inc. and Warner Chilcott in connection with the consummation of the transactions which are further described in Note 5. | ||||
| The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted from the accompanying consolidated financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair statement of Actavis plc’s consolidated financial position, results of operations, comprehensive income and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Company’s results of operations, comprehensive income and cash flows for the interim period are not necessarily indicative of the results of operations, comprehensive income and cash flows that it may achieve in future periods. The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions, if any. | ||||
| Acquisitions of Warner Chilcott and Actavis, Inc. | ||||
| On May 19, 2013, the Company entered into a definitive agreement (the “Transaction Agreement”) to acquire Warner Chilcott and Actavis, Inc. by means of a scheme of arrangement and merger, as further described in Note 5. The transaction was consummated on October 1, 2013. See Note 5 for more information about the transaction. | ||||
| Prior to the consummation of the transaction, the following legal entities were formed for the purpose of facilitating the transaction: | ||||
| • | Actavis Ireland Holding Limited (“AIHL”) | |||
| • | Actavis WC Holding S.à.r.l. | |||
| • | Actavis W.C. Holding Corporation | |||
| • | Actavis W.C. Holding 2 Corporation | |||
| • | Luxembourg Finance S.à.r.l. | |||
| Ordinary and Deferred Shares | ||||
| On September 30, 2013, Actavis plc issued 133,628,967 ordinary shares to AIHL, an Irish registered company, in exchange for preference shares. Through a series of transactions the 133,628,967 ordinary shares were ultimately acquired by Actavis W.C. Holding Corporation. As AIHL and Actavis W.C. Holding Corporation are wholly owned subsidiaries, these transactions were eliminated in the consolidated financial statements. In addition, at the balance sheet date, Matsack Nominees Limited (“Matsack”) owned seven ordinary shares and 40,000 deferred ordinary shares which were issued on August 30, 2013. Refer to Note 5 for further information on material events occurring after the balance sheet date. | ||||
| As of September 30, 2013, there were 1,000,000,000 ordinary shares of $0.0001 par value per share authorized and seven ordinary shares issued and outstanding at a value of $0. As of September 30, 2013, there were 40,000 deferred ordinary shares of € 1 par value per share authorized, issued and outstanding at a value of $53,121. | ||||
| Summary of Significant Accounting Policies | 9 Months Ended |
| Sep. 30, 2013 | |
| Accounting Policies [Abstract] | ' |
| Summary of Significant Accounting Policies | ' |
| NOTE 2 — Summary of Significant Accounting Policies | |
| Foreign Currency Translation | |
| The currency of the primary economic environment in which the Company operates (“the functional currency”) is the U.S. dollar. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded as general and administrative expenses in the consolidated statements of operations. | |
| Cash and Cash Equivalents | |
| The Company considers cash and cash equivalents to include cash in banks, cash held in trust, commercial paper and deposits with financial institutions that can be liquidated without prior notice or penalty. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. | |
| Recent Accounting Pronouncements | |
| In July 2013, the Financial Accounting Standards Board issued guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits as either a reduction of a deferred tax asset or a liability when a net operating loss carryforward, a similar tax loss or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance is not expected to have any impact on the Company’s consolidated financial statements. |
| Shareholders' Equity | 9 Months Ended |
| Sep. 30, 2013 | |
| Equity [Abstract] | ' |
| Shareholders' Equity | ' |
| NOTE 3 – SHAREHOLDERS’ EQUITY | |
| As of September 30, 2013, seven ordinary shares were owned by Matsack with a value of $0.0007. The holders of the ordinary shares are entitled to dividends, have voting rights and participate pro rata in the total assets of the Company in the event of the Company’s winding up. | |
| As of September 30, 2013, the 40,000 deferred ordinary shares of € 1 par value per share issued were owned by Matsack with a value of $53,121. The holders of the deferred ordinary shares are not entitled to receive dividends or vote. On a return of assets, whether in liquidation or otherwise, the deferred ordinary shares will entitle the holder to the amounts paid up on such shares after the repayment of the capital paid-up on the ordinary shares, plus the payment of $5,000,000 on each of the ordinary shares and the holders of such deferred ordinary shares (as such) will not be entitled to any further participation in the assets or profits of the Company. | |
| All proceeds from the issuance of shares were used to facilitate the establishment of the Company and its subsidiaries. | |
| On July 18, 2013, Matsack contributed $10 to the Company recognized as additional paid-in capital. |
| Related Party Transactions | 9 Months Ended |
| Sep. 30, 2013 | |
| Related Party Transactions [Abstract] | ' |
| Related Party Transactions | ' |
| NOTE 4 – RELATED PARTY TRANSACTIONS | |
| As of September 30, 2013, € 40,000 was held in trust by Matheson, a related party to Matsack. In addition, refer to Note 3 above for further discussion of the shares held by Matsack. |
| Subsequent Events | 9 Months Ended |
| Sep. 30, 2013 | |
| Subsequent Events [Abstract] | ' |
| Subsequent Events | ' |
| NOTE 5 – SUBSEQUENT EVENTS | |
| On October 1, 2013 (“at closing” or the “Closing Date”), pursuant to the Transaction Agreement, dated May 19, 2013, among Actavis, Inc., Warner Chilcott, the Company, Actavis Ireland Holding Limited, Actavis W.C. Holding LLC (now known as Actavis W.C. Holding Inc.) and Actavis W.C. Holding 2 LLC (now known as Actavis W.C. Holding 2 Inc.) (“MergerSub”), (a) the Company acquired Warner Chilcott (the “Acquisition”) pursuant to a scheme of arrangement under Section 201, and a capital reduction under Sections 72 and 74, of the Irish Companies Act of 1963 and (b) MergerSub merged with and into Actavis, Inc., with Actavis, Inc. as the surviving corporation in the merger (the “Merger” and, together with the Acquisition, the “Transactions”). Following the consummation of the Transactions, each of Actavis, Inc. and Warner Chilcott became wholly-owned subsidiaries of the Company. | |
| Pursuant to the terms of the Transaction Agreement, each Warner Chilcott ordinary share was converted into 0.160 of a Company ordinary share (the “Company Ordinary Shares”), and each of Actavis, Inc.’s common shares was converted into one Company Ordinary Share. | |
| The issuance of the Company Ordinary Shares in connection with the Transactions was registered under the Securities Act of 1933, as amended, pursuant to the Company’s registration statement on Form S-4 (File No. 333-189402) filed with the Securities and Exchange Commission and declared effective on July 31, 2013. | |
| Pursuant to Rule 12g-3(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is the successor issuer to Actavis, Inc. and to Warner Chilcott. The Company Ordinary Shares are deemed to be registered under Section 12(b) of the Exchange Act, and the Company is subject to the informational requirements of the Exchange Act, and the rules and regulations promulgated thereunder. The Company Ordinary Shares were approved for listing on the New York Stock Exchange (“NYSE”) and trade under the symbol “ACT”. | |
| Amended and Restated Actavis, Inc. Credit and Guaranty Agreements | |
| On the Closing Date and pursuant to that certain Term Loan Amendment Agreement (the “Term Amendment Agreement”), by and among Actavis, Inc., Bank of America, N.A. (“BofA”), as administrative agent thereunder, and the lenders party thereto, dated as of August 1, 2013, the Company, as parent guarantor, Actavis WC Holding S.à r.l. (the “ACT Borrower”), as borrower, Actavis, Inc., as a subsidiary guarantor, and BofA, as administrative agent, entered into that certain Amended and Restated Actavis Term Loan Credit and Guaranty Agreement (the “ACT Term Loan Agreement”), dated as of October 1, 2013. The ACT Term Loan Agreement amended and restated Actavis, Inc.’s $1.8 billion senior unsecured term loan credit facility, dated as of June 22, 2012. At closing, an aggregate principal amount of $1.6 billion was outstanding under the ACT Term Loan Agreement. | |
| On the Closing Date and pursuant to that certain Revolver Loan Amendment Agreement (the “Revolver Amendment Agreement” and, together with the Term Amendment Agreement, the “Amendment Agreements”), by and among Actavis, Inc., BofA, as administrative agent thereunder, and the lenders party thereto, dated as of August 1, 2013, the Company, as parent guarantor, the ACT Borrower, as borrower, Actavis, Inc., as a subsidiary guarantor, and BofA, as administrative agent, entered into that certain Amended and Restated Actavis Revolving Credit and Guaranty Agreement (the “ACT Revolving Credit Agreement” and, together with the ACT Term Loan Agreement, the “Amended and Restated Credit Agreements”), dated as of October 1, 2013. The ACT Revolving Credit Agreement amended and restated Actavis, Inc.’s $750 million senior unsecured revolving credit facility dated as of September 16, 2011, as amended by that certain Amendment No. 1 to Credit Agreement and Joinder Agreement, dated as of May 21, 2012. At closing, $6.7 million of letters of credit were outstanding under the ACT Revolving Credit Agreement. At closing, no loans were outstanding under the ACT Revolving Credit Agreement. | |
| WC Term Loan Credit and Guaranty Agreement | |
| On the Closing Date, Warner Chilcott Corporation (“WC Corporation”), WC Luxco S.à r.l. (“WC Luxco”), Warner Chilcott Company, LLC (“WC Company” and, together with WC Corporation and WC Luxco, the “WC Borrowers”), as borrowers, and Warner Chilcott Finance LLC, as a subsidiary guarantor, became parties to that certain WC Term Loan Credit and Guaranty Agreement (the “WC Term Loan Agreement”), dated as of August 1, 2013, by and among the Company, as parent guarantor, BofA, as administrative agent thereunder and a syndicate of banks participating as lenders. Pursuant to the WC Term Loan Agreement, on the Closing Date, the lenders party thereto provided term loans to the WC Borrowers in a total aggregate principal amount of $2.0 billion, comprised of (i) a tranche pursuant to which loans were made in US Dollars to each of the WC Borrowers in a total aggregate principal amount of $1.0 billion, which loans will mature on the third anniversary of the Closing Date and (ii) a tranche pursuant to which loans were made in US Dollars to each of the WC Borrowers in a total aggregate principal amount of $1.0 billion, which loans will mature on the fifth anniversary of the Closing Date. The proceeds of borrowings under the WC Term Loan Agreement were used to finance, in part, the repayment in full of all amounts owing under that certain Credit Agreement, dated as of March 17, 2011, as amended by Amendment No. 1 on August 20, 2012, among Warner Chilcott Holdings Company III, Limited, the WC Borrowers, BofA, as administrative agent thereunder and a syndicate of banks participating as lenders. | |
| Actavis, Inc. Supplemental Indenture | |
| On October 1, 2013, the Company, Actavis, Inc. and Wells Fargo Bank, National Association, as trustee, entered into a fourth supplemental indenture (the “Fourth Supplemental Indenture”) to the indenture, dated as of August 24, 2009 (the “Base Indenture” and, together with the First Supplemental Indenture, the Second Supplemental Indenture and the Third Supplemental Indenture (each as defined below), the “Indenture”), as supplemented by the first supplemental indenture, dated as of August 24, 2009 (the “First Supplemental Indenture”), the second supplemental indenture, dated as of May 7, 2010 (the “Second Supplemental Indenture”), and the third supplemental indenture, dated as of October 2, 2012 (the “Third Supplemental Indenture”). Pursuant to the Fourth Supplemental Indenture, the Company has provided a full and unconditional guarantee of Actavis, Inc.’s obligations under its 5.000% Senior Notes due August 15, 2014, (the “2014 Notes”), 6.125% Senior Notes due August 15, 2019 (the “2019 Notes”), 1.875% Senior Notes due 2017 (the “2017 Notes”), 3.250% Senior Notes due 2022 (the “2022 Notes”) and 4.625% Senior Notes due 2042 (the “2042 Notes”, and together with the 2014 Notes, the 2019 Notes, the 2017 Notes and the 2022 Notes, the “Notes”). | |
| On October 18, 2013, Actavis, Inc., a wholly-owned subsidiary of the Company, instructed Wells Fargo Bank, National Association, as trustee (the “Trustee”), pursuant to the Indenture governing its 2014 Notes, to issue a notice from Actavis, Inc. to the holders of the 2014 Notes that Actavis, Inc. has elected to redeem in full the entire aggregate principal amount of the 2014 Notes on November 5, 2013 (the “Redemption Date”). The 2014 Notes, which have an outstanding principal balance of $450.0 million and which are fully and unconditionally guaranteed by the Company, will be redeemed at a redemption price equal to the sum of the present values of the remaining scheduled payments of principal and interest on the 2014 Notes from the Redemption Date to August 15, 2014, discounted to the Redemption Date on a semi-annual basis at the Treasury Rate (as defined in the Indenture), plus 40 basis points, plus accrued and unpaid interest, if any, to, but excluding, the Redemption Date. | |
| WC Supplemental Indenture | |
| On October 1, 2013, the Company, WC Company, Warner Chilcott Finance LLC (the “Co-Issuer” and together with WC Company, the “Issuers”) and Wells Fargo Bank, National Association, as trustee (the “WC Trustee”), entered into a third supplemental indenture (the “Supplemental Indenture”) to the indenture, dated as of August 20, 2010 (the “WC Indenture”), among the Issuers, the guarantors party thereto and the WC Trustee, with respect to the Issuers’ 7.75% senior notes due 2018 (the “WC Notes”). Pursuant to the Supplemental Indenture, the Company has provided a full and unconditional guarantee of the Issuers’ obligations under the WC Notes and the WC Indenture. | |
| On October 1, 2013, the Issuers and the Trustee entered into a Release of Guarantees of Certain Guarantors (the “Release of Guarantees”), pursuant to which Warner Chilcott’s guarantee of the WC Notes was released in accordance with Section 11.05(f) of the WC Indenture and the guarantees of certain other guarantors were released in accordance with Section 11.05(c) or 11.05(e) of the WC Indenture. | |
| Indemnification Agreements | |
| Effective October 1, 2013, the Company entered into deeds of indemnification (the “Deeds of Indemnification”) with certain of the Company’s directors and officers. The Deeds of Indemnification provide indemnification to such directors and officers to the fullest extent permitted by the laws of Ireland, and in accordance with the Company’s Memorandum and Articles of Association, for all expenses actually and reasonably incurred in any action or proceeding in which the officer or director is or may be involved in by reason of the fact that he or she is or was a Company officer or director, on the terms and conditions set forth in the Deeds of Indemnification. Further, the Company agrees to advance expenses incurred in defense of these proceedings, on the terms and conditions set forth in the Deeds of Indemnification. The Deeds of Indemnification also provide procedures for requesting and obtaining indemnification and advancement of expenses. | |
| Effective October 1, 2013, Actavis W.C. Holding Inc. (“U.S. Holdco”), an indirectly wholly-owned subsidiary of the Company, entered into indemnification agreements (the “Holdco Indemnification Agreements”) with certain directors and executive officers of the Company. The Holdco Indemnification Agreements provide indemnification to such directors and officers to the fullest extent permitted by the General Corporation Law of Delaware, and in accordance with U.S. Holdco’s Bylaws, for all expenses actually and reasonably incurred in any action or proceeding in which the director or officer is or may be involved by reason of the fact that he or she is or was a U.S. Holdco director or officer, on the terms and conditions set forth in the Holdco Indemnification Agreements. Further, U.S. Holdco agrees to advance expenses incurred in defense of these proceedings, on the terms and conditions set forth in the Holdco Indemnification Agreements. The Holdco Indemnification Agreements also provide procedures for requesting and obtaining indemnification and advancement of expenses. | |
| On October 1, 2013, in connection with the consummation of the Transactions, the Company amended and restated its Memorandum and Articles of Association. | |
| Other subsequent events | |
| On October 1, 2013, Matsack transferred legal ownership of their seven Company Ordinary Shares of Actavis plc to Actavis plc and transferred their 40,000 deferred ordinary shares to Actavis, Inc. On the same day, Actavis, Inc. transferred the 40,000 deferred ordinary shares to Watson Pharma International Holding S.à.r.l. | |
| On October 28, 2013, Warner Chilcott Company, LLC (“WCCL”), an indirect wholly-owned subsidiary of the Company, and Sanofi- Aventis U.S. LLC (“Sanofi”) entered into an amendment (the “Amendment”) to the global collaboration agreement (as amended, the “Collaboration Agreement”) to which WCCL and Sanofi are parties. Under the Collaboration Agreement, about which you may find additional information in the Warner Chilcott plc’s Annual Report on Form 10-K for the year ended December 31, 2012, WCCL and Sanofi co-develop and market Actonel ® and Atelvia ® (risedronate sodium) on a global basis, excluding Japan. | |
| Pursuant to the Amendment, the parties amended the Collaboration Agreement with respect to ACTONEL ® and ATELVIA ® in the U.S. and Puerto Rico (the “Exclusive Territory”) to provide that, in exchange for the payment of a lump sum of $125.0 million by WCCL to Sanofi no later than December 2, 2013, WCCL’s obligations with respect to the global reimbursement payment as it relates to the Exclusive Territory for the year ended December 31, 2014 shall be satisfied in full. The Amendment does not apply to or affect the parties’ respective rights and obligations under the Collaboration Agreement with respect to (i) the remainder of 2013 or (ii) territories outside the Exclusive Territory. |
| General (Policies) | 9 Months Ended | |||
| Sep. 30, 2013 | ||||
| Accounting Policies [Abstract] | ' | |||
| Acquisition of Warner Chilcott | ' | |||
| Acquisitions of Warner Chilcott and Actavis, Inc. | ||||
| On May 19, 2013, the Company entered into a definitive agreement (the “Transaction Agreement”) to acquire Warner Chilcott and Actavis, Inc. by means of a scheme of arrangement and merger, as further described in Note 5. The transaction was consummated on October 1, 2013. See Note 5 for more information about the transaction. | ||||
| Prior to the consummation of the transaction, the following legal entities were formed for the purpose of facilitating the transaction: | ||||
| • | Actavis Ireland Holding Limited (“AIHL”) | |||
| • | Actavis WC Holding S.à.r.l. | |||
| • | Actavis W.C. Holding Corporation | |||
| • | Actavis W.C. Holding 2 Corporation | |||
| • | Luxembourg Finance S.à.r.l. | |||
| Ordinary and Deferred Shares | ' | |||
| Ordinary and Deferred Shares | ||||
| On September 30, 2013, Actavis plc issued 133,628,967 ordinary shares to AIHL, an Irish registered company, in exchange for preference shares. Through a series of transactions the 133,628,967 ordinary shares were ultimately acquired by Actavis W.C. Holding Corporation. As AIHL and Actavis W.C. Holding Corporation are wholly owned subsidiaries, these transactions were eliminated in the consolidated financial statements. In addition, at the balance sheet date, Matsack Nominees Limited (“Matsack”) owned seven ordinary shares and 40,000 deferred ordinary shares which were issued on August 30, 2013. Refer to Note 5 for further information on material events occurring after the balance sheet date. | ||||
| As of September 30, 2013, there were 1,000,000,000 ordinary shares of $0.0001 par value per share authorized and seven ordinary shares issued and outstanding at a value of $0. As of September 30, 2013, there were 40,000 deferred ordinary shares of € 1 par value per share authorized, issued and outstanding at a value of $53,121. | ||||
| Foreign Currency Translation | ' | |||
| Foreign Currency Translation | ||||
| The currency of the primary economic environment in which the Company operates (“the functional currency”) is the U.S. dollar. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded as general and administrative expenses in the consolidated statements of operations. | ||||
| Cash and Cash Equivalents | ' | |||
| Cash and Cash Equivalents | ||||
| The Company considers cash and cash equivalents to include cash in banks, cash held in trust, commercial paper and deposits with financial institutions that can be liquidated without prior notice or penalty. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. | ||||
| Recent Accounting Pronouncements | ' | |||
| Recent Accounting Pronouncements | ||||
| In July 2013, the Financial Accounting Standards Board issued guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits as either a reduction of a deferred tax asset or a liability when a net operating loss carryforward, a similar tax loss or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance is not expected to have any impact on the Company’s consolidated financial statements. | ||||
| General - Additional Information (Detail) | 1 Months Ended | 1 Months Ended | 3 Months Ended | |||||||||
| 16-May-13 | Sep. 30, 2013 | 16-May-13 | Sep. 18, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | |
| USD ($) | Private Limited Company [Member] | Public Limited Company [Member] | Deferred Shares [Member] | Deferred Shares [Member] | Actavis Ireland Holding Limited [Member] | W.C. Holding Corporation [Member] | Matsack [Member] | Matsack [Member] | Matsack [Member] | Warner Chilcott and Actavis Inc [Member] | ||
| USD ($) | EUR (€) | USD ($) | Deferred Shares [Member] | Deferred Shares [Member] | ||||||||
| USD ($) | EUR (€) | |||||||||||
| Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Date of incorporation as a limited company | ' | ' | 16-May-13 | 18-Sep-13 | ' | ' | ' | ' | ' | ' | ' | ' |
| Incorporated country | 'Ireland | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Business acquisition date | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 19-May-13 |
| Ordinary shares, issued | ' | 7 | ' | ' | 40,000 | 40,000 | 133,628,967 | 133,628,967 | 7 | 40,000 | 40,000 | ' |
| Ordinary shares, authorized | ' | 1,000,000,000 | ' | ' | 40,000 | 40,000 | ' | ' | ' | ' | ' | ' |
| Ordinary shares, par value | ' | $0.00 | ' | ' | ' | € 1 | ' | ' | ' | ' | € 1 | ' |
| Ordinary shares, outstanding | ' | 7 | ' | ' | 40,000 | 40,000 | ' | ' | 7 | ' | ' | ' |
| Ordinary shares, value | ' | $53,121 | ' | ' | $53,121 | ' | ' | ' | $0.00 | $53,121 | ' | ' |
| Shareholders' Equity - Additional Information (Detail) | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Jul. 18, 2013 | Sep. 30, 2013 | Sep. 30, 2013 |
| USD ($) | Deferred Shares [Member] | Deferred Shares [Member] | Matsack [Member] | Matsack [Member] | Matsack [Member] | Matsack [Member] | |
| USD ($) | EUR (€) | USD ($) | USD ($) | Deferred Shares [Member] | Deferred Shares [Member] | ||
| USD ($) | EUR (€) | ||||||
| Equity [Line Items] | ' | ' | ' | ' | ' | ' | ' |
| Ordinary shares, outstanding | 7 | 40,000 | 40,000 | 7 | ' | ' | ' |
| Ordinary shares, value | $53,121 | $53,121 | ' | $0.00 | ' | $53,121 | ' |
| Ordinary shares, issued | 7 | 40,000 | 40,000 | 7 | ' | 40,000 | 40,000 |
| Ordinary shares, par value | $0.00 | ' | € 1 | ' | ' | ' | € 1 |
| Payment in addition to repayment of capital paid-up on ordinary shares | 5,000,000 | ' | ' | ' | ' | ' | ' |
| Additional paid-in capital | $10 | ' | ' | ' | $10 | ' | ' |
| Related Party Transactions - Additional Information (Detail) (Matheson [Member], EUR €) | Sep. 30, 2013 |
| Matheson [Member] | ' |
| Assets held in trust | € 40,000 |
| Subsequent Events - Additional Information (Detail) (Subsequent Event [Member], USD $) | 1 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | ||||||||||||||
| In Millions, except Share data, unless otherwise specified | Oct. 03, 2013 | Oct. 28, 2013 | Oct. 18, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 03, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 | Oct. 01, 2013 |
| 5.000% Senior Notes due August 15, 2014 [Member] | 5.000% Senior Notes due August 15, 2014 [Member] | 6.125% Senior Notes due August 15, 2019 [Member] | 1.875% Senior Notes due 2017 [Member] | 3.250% Senior Notes due 2022 [Member] | 4.625% Senior Notes due 2042 [Member] | Warner Chilcott Plc [Member] | Actavis Inc [Member] | Watson Pharma International Holding [Member] | ACT Term Loan [Member] | Amended and Restated Credit Agreements [Member] | ACT Revolving Credit Agreement [Member] | Term Loan Agreement [Member] | Term Loan Agreement [Member] | Term Loan Agreement [Member] | Term Loan Agreement [Member] | |||
| Letter of Credit [Member] | 7 3/4% senior notes due 2018 [Member] | Tranche One [Member] | Tranche Two [Member] | |||||||||||||||
| Subsequent Event [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Ordinary shares, conversion ratio | ' | ' | ' | ' | ' | ' | ' | ' | 0.16 | 1 | ' | ' | ' | ' | ' | ' | ' | ' |
| Maximum borrowing capacity | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,800 | $750 | ' | $2,000 | ' | $1,000 | $1,000 |
| Aggregate principal amount outstanding | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,600 | ' | 6.7 | ' | ' | ' | ' |
| Senior notes, interest rate | ' | ' | ' | 5.00% | 6.13% | 1.88% | 3.25% | 4.63% | ' | ' | ' | ' | ' | ' | ' | 7.75% | ' | ' |
| Senior Notes, Redemption Description | ' | ' | 'On October 18, 2013, Actavis, Inc., a wholly-owned subsidiary of the Company, instructed Wells Fargo Bank, National Association, as trustee (the "Trustee"), pursuant to the Indenture governing its 2014 Notes, to issue a notice from Actavis, Inc. to the holders of the 2014 Notes that Actavis, Inc. has elected to redeem in full the entire aggregate principal amount of the 2014 Notes on November 5, 2013 (the "Redemption Date"). The 2014 Notes, which have an outstanding principal balance of $450.0 million and which are fully and unconditionally guaranteed by the Company, will be redeemed at a redemption price equal to the sum of the present values of the remaining scheduled payments of principal and interest on the 2014 Notes from the Redemption Date to August 15, 2014, discounted to the Redemption Date on a semi-annual basis at the Treasury Rate (as defined in the Indenture), plus 40 basis points, plus accrued and unpaid interest, if any, to, but excluding, the Redemption Date. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Senior notes, redemption date | ' | ' | 5-Nov-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Senior notes, redemption end date | ' | ' | 15-Aug-14 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Outstanding principal balance | ' | ' | 450 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest rate basis spread | ' | ' | 0.40% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Maturity of senior notes | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '2018 | ' | ' |
| Number of ordinary shares transferred by Matsack to Actavis, Inc | 7 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Number of deferred shares transferred by Actavis, Inc to Watson Pharma International Holding | 40,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 40,000 | ' | ' | ' | ' | ' | ' | ' |
| Payment respect to global reimbursement | ' | $125 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
